#Japan #Tokyo #Liquid Biopsy #SOPHiA GENETICS #A.D.A.M. Innovations

A Strategic Alliance for Advancing Cancer Care in Japan

In a groundbreaking collaboration, A.D.A.M. Innovations, a prominent genetic testing firm in Japan, has partnered with SOPHiA GENETICS, a leader in AI-driven technology, to revolutionize liquid biopsy testing and companion diagnostics for precision oncology in Japan. This significant venture was announced at the European Society for Medical Oncology (ESMO) Congress 2025.

What is Liquid Biopsy?

Liquid biopsy represents a non-invasive method for detecting and analyzing tumor DNA from a simple blood sample. This innovative approach allows for real-time insights into the genomic characteristics of cancers, paving the way toward more personalized and effective cancer treatment options. By integrating the capabilities of both companies, this partnership aims to enhance access to advanced cancer genomics for patients across Japan.

A.D.A.M. Innovations: Pioneers in Genetic Testing

Founded in 2004 and located in Tokyo, A.D.A.M. Innovations has positioned itself as a leader in the private genetic testing market. With over two decades of experience, it has conducted more than 2.8 million genomic tests and has established a high-throughput laboratory to support its operations. Its extensive experience and local presence are crucial in implementing the innovative solutions developed in this partnership with SOPHiA GENETICS.

The Role of SOPHiA GENETICS

SOPHiA GENETICS specializes in data-driven medicine and offers the SOPHiA DDM™ Platform, an advanced technology founded on artificial intelligence that enables healthcare institutions to analyze complex genomic and multimodal data. The partnership will leverage this cutting-edge AI technology to enable faster and more accurate identification of actionable genomic alterations using the MSK-ACCESS® liquid biopsy application.

Enhancing Patient Care and Drug Development

One of the primary goals of this collaboration is to launch the liquid biopsy test locally, which will facilitate expedited testing times and reduced costs for patients. Moreover, as part of their efforts, both companies plan to develop a liquid biopsy companion diagnostic test that is expected to enhance personalized healthcare solutions significantly. This development will not only benefit patients but also provide pharmaceutical partners with important tools to propel drug development, thereby streamlining the path to market access in Japan.

A Focus on Accessibility

According to Ross Muken, President of SOPHiA GENETICS, this partnership underlines a commitment to increasing the accessibility of precision oncology. "Combining our AI capabilities with A.D.A.M. Innovations' expertise in clinical genomics positions us to lead the charge in making data-driven medicine a reality for all cancer patients in Japan."

Michel Mommejat, President of A.D.A.M. Innovations, echoed the sentiment, stating, "Through this partnership, we are taking significant strides toward advancing cancer diagnostics and improving patient outcomes nationwide."

Future Prospects

The formal announcement made during the ESMO Congress signifies a pivotal move toward optimizing cancer care through technology and collaboration. With the potential to significantly influence the landscape of oncological treatment in Japan, this partnership opens pathways for enhanced clinical research and personalized treatment strategies.

Those interested in learning more about the collaborative efforts between SOPHiA GENETICS and A.D.A.M. Innovations can visit their booths at the ongoing ESMO conference from October 17 to 21, 2025.

This cooperation promises to not only transform the diagnostics and treatment modalities available to Japanese patients but also set a precedent for future partnerships in the healthcare industry. Together, these two powerhouse organizations are poised to lead the charge in innovative cancer care, combining advanced technology with a deep understanding of local healthcare needs.